6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the month of October 2021

Commission File Number 001-40316

VECTIVBIO HOLDING AG

(Exact name of registrant as specified in its charter)

Aeschenvorstadt 36

4051 Basel

Switzerland

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

VectivBio Holding AG is submitting this Report on Form 6-K to furnish its (i) unaudited interim condensed consolidated statement of financial position as of June 30, 2021 and (ii) unaudited interim condensed consolidated statement of income (loss) for the six months ended June 30, 2021, which are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Report on Form 6-K.

Exhibits
99.1	Unaudited Interim Condensed Consolidated Statement of Financial Position for the Six Months Ended June 30, 2021
99.2	Unaudited Interim Condensed Consolidated Statement of Income (Loss) for the Six Months Ended June 30, 2021

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	VECTIVBIO HOLDING AG
October 29, 2021	By:	/s/ Claudia D'Augusta
		Claudia D’Augusta
		Chief Financial Officer

EX-99.1

VectivBio Holding AG

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

In thousands of USD
	As of,
	June 30, 2021		December 31, 2020
ASSETS
NON-CURRENT ASSETS
Property, plant and equipment	115		173
Goodwill	918		901
Intangible assets	22,171		21,758
Right-of-use assets	98		114
Financial assets	61		64
Total non-current assets	23,363		23,010
CURRENT ASSETS
Other current receivables	523		963
Other current assets	6,706		6,417
Cash and cash equivalents	144,610		40,172
Total current assets	151,839		47,552
Total assets	175,202		70,562
EQUITY AND LIABILITIES
EQUITY
Net parent investment	—		—
Share capital	1,856		1,370
Reserves	242,419		101,933
Accumulated losses		(103,873)	(71,065)
Total equity	140,402		32,238
NON-CURRENT LIABILITIES
Lease liabilities	—		4
Net pension liabilities	2,997		3,557
Total non-current liabilities	2,997		3,561
CURRENT LIABILITIES
Current liabilities related to business combinations	20,000		—
Contingent consideration liabilities	—		19,140
Trade payables	3,062		9,490
Accrued expenses	7,897		5,247
Other current liabilities	745		774
Lease liabilities	99		112
Total current liabilities	31,803		34,763
Total liabilities	34,800		38,324
Total equity and liabilities	175,202		70,562

EX-99.2

VectivBio Holding AG

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)

In thousands of United States dollars ("USD")
	Six Month Ended June 30,
	2021		2020
CONSOLIDATED STATEMENTS OF OPERATIONS
Research and development expenses	(26,494	)	(10,660)
General and administrative expenses	(19,097	)	(5,405)
Operating loss	(45,591)		(16,065)
Finance income	—		15
Finance expense	(23)		(1,096)
Foreign exchange differences, net	496		(517)
Loss before income taxes	(45,118)		(17,677)
Income taxes	—		—
Net loss	(45,118)		(17,677)
Remeasurement of net pension liabilities	508		(511)
Total items that will not be reclassified subsequently to profit or loss	508		(670)
Exchange differences arising on translation of foreign operations	(113)		(670)
Total items that may be reclassified subsequently to profit or loss	(113)		(670)
Total other comprehensive loss, net of income tax	395		(1,181)
Total comprehensive loss	(44,723)		(18,858)
LOSS PER SHARE
Basic and diluted loss per share (in USD)	(2.08)		(1.85)